Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
X-linked Traits01:19

X-linked Traits

59.5K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
59.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.3K
Introduction to Hemostasis01:05

Introduction to Hemostasis

16.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
16.3K
Pedigree Analysis01:35

Pedigree Analysis

90.8K
Overview
90.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Hemophilia Care: Real-World Outcomes Following Switching to Extended Half-Life Factor VIII in Greece-The TOOL Study.

Life (Basel, Switzerland)·2026
Same author

Disease burden and unmet medical need in severe hemophilia in Greece: insights from clinicians and patients.

Frontiers in public health·2026
Same author

Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal.

Expert review of pharmacoeconomics & outcomes research·2025
Same author

Thrombotic Complications in Pediatric Cancer.

Children (Basel, Switzerland)·2024
Same author

Pediatric Central Retinal Artery Occlusion Attributed to a Patent Ductus Arteriosus.

Cureus·2024
Same author

Genetic predictors for FVIII inhibitors formation in a Greek population of children with severe haemophilia A exclusively treated with recombinant concentrates.

Haemophilia : the official journal of the World Federation of Hemophilia·2024

Related Experiment Video

Updated: Mar 29, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.8K

Hemophilia's Overlooked Female Face.

Alkistis Adramerina1, Marina Economou1

  • 11st Pediatric Department, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital, 546 42 Thessaloniki, Greece.

Journal of Clinical Medicine
|March 28, 2026
PubMed
Summary

Female hemophilia carriers experience bleeding issues and are often underdiagnosed. Current healthcare practices need reevaluation to address their unique needs and improve management strategies for hemophilia in women.

Keywords:
bleeding tendencycarrierfemalehemophilia

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

88
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Related Experiment Videos

Last Updated: Mar 29, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.8K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

88
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Area of Science:

  • Hematology
  • Genetics
  • Women's Health

Background:

  • Hemophilia is increasingly recognized beyond a male-only disorder, with female carriers showing significant bleeding tendencies.
  • Females can present with hemophilia severity similar to males, complicated by gynecological and obstetric bleeding.
  • The term 'hemophilia carrier' historically implies normal hemostasis, leading to underdiagnosis and inadequate care for affected women.

Purpose of the Study:

  • To highlight the underdiagnosed bleeding issues in female hemophilia carriers.
  • To emphasize the need for reevaluation of diagnostic and treatment paradigms for women with hemophilia.
  • To advocate for increased research and improved healthcare infrastructure for this patient population.

Main Methods:

  • Review of current understanding of hemophilia in females.
  • Analysis of factors contributing to underdiagnosis and inadequate treatment.
  • Discussion of limitations in clinical trials and hemophilia center expertise.

Main Results:

  • Female hemophilia carriers frequently experience overlooked bleeding symptoms.
  • Gynecological and obstetric bleeding in females may not correlate with factor levels.
  • Females with hemophilia are underrepresented in clinical research and often lack specialized care.

Conclusions:

  • Established management practices for hemophilia require reevaluation to include females.
  • Further research and larger studies are crucial to understand and address the needs of females with hemophilia.
  • Improved infrastructure and expertise in hemophilia centers are necessary for effective female patient management.